key: cord-1006898-tcc1z4ce
authors: Shewale, Jaiprakash G.; Ratcliff, James L.
title: Overinterpretation of the antiviral results for human coronavirus strain 229E (HCoV‐229E) relative to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
date: 2021-01-05
journal: J Med Virol
DOI: 10.1002/jmv.26722
sha: fc920cb9accc3d18b94cdf9759bc421c3cfb88a0
doc_id: 1006898
cord_uid: tcc1z4ce

Published reports provide evidence that the antiviral activity of products against human coronavirus (HCoV) 229E, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) or other viruses may not be generalized to the antiviral activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This article is protected by copyright. All rights reserved.

The recent article by Meyers et al. 1 suffers from several interpretation issues that are not supported by the results and thereby it has the potential to mislead readers regarding health claims related to the current SARS-CoV-2 pandemic. The aforementioned article already received some criticism from the scientific community and mainstream print media. 2 We provide additional observations on this article and on research pertaining to use of oral care products in reducing SARS-CoV-2 viral load.

The title overstates the investigation. The "Lowering the transmission and spread" of an infectious virus can be claimed only after proper in vivo or clinical studies have been conducted.

HCoV strains 229E, NL63, OC43, and HKU1 account for approximately one third of the cases of the common cold, are not as highly contagious, and do not manifest mortality rates comparable to SARS-CoV, SARS-CoV-2, or MERS-CoV. 3 emphasizing that the differences in the chemical structure of each of these unique spike proteins is critically important to the physiologic and pathologic response by the human host. 11 We find more robust studies of the reduction of SARS-CoV-2 viral load by oral care products emerging in the literature. Meister et al. 7 reported that the antiviral activity of eight different products varied when each was applied to three different strains of SARS-CoV-2. Oral

Lowering the transmission and spread of human coronavirus

Mouthwash will not save you from the coronavirus

Overview of lethal human coronaviruses

Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?

Cell line authentication publication requirements

Virucidal efficacy of different oral rinses against severe acute respiratory syndrome coronavirus 2

In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens

Evaluation of the antiviral activity of chlorine dioxide and sodium hypochlorite against feline calicivirus, human Influenza virus, Measles virus, canine distemper virus, human herpesvirus, human adenovirus, canine adenovirus and canine parvovirus

Subtle differences in virus composition affect disinfection kinetics and mechanisms

Novel coronavirus structure reveals targets for vaccines and treatments

Assessment of CloSYS Ultra Sensitive Rinse (CloSYS Unflavored Rinse) against SARS-CoV-2, Final

SARS-associated Coronavirus (SARS-CoV)

Microbac Laboratories. Final Report, Virucidal Efficacy Suspension Test, Influenza A virus (H3N2)

Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) (COVID-19 virus

Assessment of CloSYS Oral Spray against SARS-CoV-2, Final Report

Assessment of CloSYS Sensitive Rinse (CloSYS GentleMint Flavored Rinse) against SARS-CoV-2, Final

Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse